Results of GSK and AstraZeneca trials may widen ovarian cancer drug use
GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class.
from Reuters: Health News https://ift.tt/2nmOMv4
from Reuters: Health News https://ift.tt/2nmOMv4
Comentarii
Trimiteți un comentariu